Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone

Journal of Clinical Psychopharmacology

Volumn 24, Issue 3, 2004, Pages 260-267

  Reveley, Michael A ^a   Libretto, Susan E ^b  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b Janssen Cilag Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

ADULT; AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; THOUGHT DISORDER; TREATMENT FAILURE; TREATMENT OUTCOME; TREMOR; UNITED KINGDOM; VIRUS INFECTION; VOMITING;

ADOLESCENT; ADULT; CHRONIC DISEASE; COHORT STUDIES; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME; TREATMENT FAILURE;

EID: 2442662967     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000126661.58411.d3     Document Type: Article

References (19)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 1997; 349:1436-1442.
2. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry. 1999;60:4-6.
3. Van Putten T. Drug refusal in schizophrenia: causes and prescribing hints. Hosp Comm Psychiatry. 1978;29:110-112.
4. Kane JM. Compliance in long-term treatment of schizophrenia. Psychopharmacol Bull. 1985;2:23-27.
5. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:325-351.
6. Kane JM. Pharmacological treatment of schizophrenia. Biol Psychiatry. 1999;46:1396-1408.
7. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
8. Marder SR, Meibach RC. Risperidone in the treatment is schizophrenia. Am J Psychiatry. 1994;151:825-835.
9. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
10. Arvanitis LAS, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997;42: 233-246.
11. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analyses: combined results of the North American trials. J Clin Psychiatry. 1997;58: 538-546.
12. Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
13. Kay SR, Fiszbein A, Opler LA. The positive-negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
14. US Department of Health EAW. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338 ed. Washington, DC: US Department of Health, Education and Welfare; 1976.
15. Elvevag B, Weinstock DM, Akil M, et al. A comparison of verbal fluency tasks in schizophrenic patients and normal controls. Schizophr Res. 2001;51:119-126.
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Publication ADM 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537.
17. Simpson GM, Lee JH, Zoubok B, et al. A rating scale for tardive dyskinesia. Psychopharmacology. 1979;64:171-179.
18. Chouinard G, Jones B, Remington G, et al. A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40.
19. Peuskens J, The Risperidone Study Group. Risperidone in the treatment of chronic schizophrenic patients: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995; 166:713-726.